Status | Study |
Completed |
Study Name: Haemolytic Uraemic Syndrome in Childhood: Clinical, Cognitive and Psychological Aspects Condition: Hemolytic-Uremic Syndrome Children Date: 2012-07-31 |
Recruiting |
Study Name: Atypcial Hemolytic-Uremic Syndrome (aHUS) Registry Condition: Atypical Hemolytic-Uremic Syndrome Date: 2012-01-18 |
Terminated |
Study Name: aHUS Observational Long Term Follow-Up Condition: Atypical Hemolytic Uremic Syndrome Date: 2012-01-18 |
Withdrawn |
Study Name: The Plasma Large-Volume Exchange RCT Condition: Purpura, Thrombotic Thrombocytopenic Hemolytic Uremic Syndrome Date: 2011-09-09 Interventions: Procedure: Plasma Exchange Plasma exchange is a blood purification technique that removes plasma from th |
Completed |
Study Name: Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) Condition: Shiga-like Toxin-producing Escherichia Coli Date: 2011-08-03 Interventions: Drug: Eculizumab (Soliris®) Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intra |
Completed |
Study Name: Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4 Condition: Hemolytic-uremic Syndrome Escherichia Coli Infections Date: 2011-07-28 Interventions: Other: HUS standard coverage care (including in ICU) HUS standard coverage care : plasmaphereses - eculi |
Completed |
Study Name: An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome Condition: Atypical Hemolytic-Uremic Syndrome Date: 2010-08-31 Interventions: Drug: Eculizumab All patients received open-label eculizumab administered intravenously on the following |
Completed |
Study Name: An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome Condition: Atypical Hemolytic-Uremic Syndrome Date: 2010-08-31 Interventions: Drug: Eculizumab Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient |
Completed |
Study Name: Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease Condition: Atypical Hemolytic Uraemic Syndrome. Date: 2009-06-29 |
Completed |
Study Name: Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS Condition: Atypical Hemolytic Uremic Syndrome Date: 2009-02-13 Interventions: Drug: Eculizumab All patients received open-label eculizumab administered intravenously on the following |